title: Update on denosumab treatment in postmenopausal women with osteoporosis.
abstract: Denosumab, a fully human recombinant monoclonal antibody to the receptor activator of nuclear factor-κB ligand (RANKL), blocks binding of RANKL to the RANK receptor, found on the surface of osteoclasts and osteoclast precursors, resulting in decreased bone resorption. Subcutaneous denosumab administration once every 6 months increases bone mineral density at the lumbar spine, total hip, and/or femoral neck, and reduces markers of bone turnover significantly in postmenopausal women with osteoporosis. Relative to placebo, denosumab treatment reduces the risk of vertebral, nonvertebral, and hip fractures significantly. The benefits of denosumab treatment are generally obvious after the first dose and were continued for up to 8 years of treatment in an extension study. The tolerability profile of denosumab during this extension phase was consistent with that observed during the initial 3-year FREEDOM trial. Postmarketing safety surveillance has not shown any unexpected findings. Ongoing safety surveillance will more fully define the long-term safety of denosumab. The benefits of denosumab would seem to be greater than its risks. Denosumab is an important choice in the treatment of postmenopausal women with osteoporosis at increased risk of fractures, including older patients who have difficulty with oral bisphosphonate intake and patients who are intolerant of, or unresponsive to, other therapies.
authors.affiliation: Division of Endocrinology and Metabolism, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. ykmin@skku.edu.
authors.forename: Yong Ki
authors.initials: YK
authors.lastname: Min
keywords: Denosumab; Fracture; Osteoporosis
references.citation: J Bone Miner Res. 2004 Jul;19(7):1059-66
references.pmid: 15176987
references.citation: J Clin Endocrinol Metab. 2011 Jun;96(6):1727-36
references.pmid: 21411557
references.citation: J Clin Endocrinol Metab. 2011 Apr;96(4):972-80
references.pmid: 21289258
references.citation: J Bone Miner Res. 2010 Oct;25(10):2256-65
references.pmid: 20533525
references.citation: J Bone Miner Res. 2014 Jan;29(1):158-65
references.pmid: 23794225
references.citation: J Bone Miner Res. 2011 Aug;26(8):1829-35
references.pmid: 21491487
references.citation: Drugs Aging. 2011 Jan 1;28(1):63-82
references.pmid: 21174488
references.citation: N Engl J Med. 2009 Aug 20;361(8):756-65
references.pmid: 19671655
references.citation: J Bone Miner Res. 2014 Sep;29(9):2051-6
references.pmid: 24692050
references.citation: J Clin Densitom. 2013 Apr-Jun;16(2):147-53
references.pmid: 22521543
references.citation: J Bone Miner Res. 2010 Jan;25(1):72-81
references.pmid: 19594293
references.citation: J Bone Miner Res. 2012 Sep;27(9):1879-86
references.pmid: 22532494
references.citation: J Bone Miner Res. 2007 Dec;22(12):1832-41
references.pmid: 17708711
references.citation: J Bone Miner Res. 2012 Jan;27(1):211-8
references.pmid: 21976367
references.citation: J Bone Miner Res. 2009 Jan;24(1):153-61
references.pmid: 18767928
references.citation: Drugs. 2011 Jan 1;71(1):65-78
references.pmid: 21175240
references.citation: Lancet. 2013 Jul 6;382(9886):50-6
references.pmid: 23683600
references.citation: J Bone Miner Res. 2012 Mar;27(3):694-701
references.pmid: 22113951
references.citation: N Engl J Med. 2006 Feb 23;354(8):821-31
references.pmid: 16495394
references.citation: Osteoporos Int. 2013 Jan;24(1):227-35
references.pmid: 22776860
references.citation: Indian J Endocrinol Metab. 2014 Jul;18(4):449-54
references.pmid: 25143898
references.citation: Osteoporos Int. 2014 Apr;25(4):1313-9
references.pmid: 24345885
references.citation: J Bone Joint Surg Am. 2012 Dec 5;94(23):2113-9
references.pmid: 23097066
references.citation: J Bone Miner Res. 2013 Apr;28(4):746-52
references.pmid: 23109251
references.citation: J Bone Miner Res. 2014 Feb;29(2):450-7
references.pmid: 23873632